{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:00:57Z","timestamp":1767888057590,"version":"3.49.0"},"reference-count":84,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1097\/aci.0b013e328364d86a","type":"journal-article","created":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T09:38:02Z","timestamp":1377250682000},"page":"550-557","source":"Crossref","is-referenced-by-count":28,"title":["Immunomodulators for conjunctivitis"],"prefix":"10.1097","volume":"13","author":[{"given":"Punchama","family":"Pacharn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pakit","family":"Vichyanond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-16-20210128","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1398-9995.2008.01884.x","article-title":"Global map of the prevalence of symptoms of rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three.","volume":"64","author":"Ait-Khaled","year":"2009","journal-title":"Allergy"},{"key":"R2-16-20210128","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1399-3038.2007.00601.x","article-title":"Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the International Study of Asthma and Allergies in Childhood.","volume":"19","author":"Bjorksten","year":"2008","journal-title":"Pediatr Allergy Immunol"},{"key":"R3-16-20210128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/09286580590967781","article-title":"The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting.","volume":"12","author":"Smith","year":"2005","journal-title":"Ophthalmic Epidemiol"},{"key":"R4-16-20210128","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1600-0420.2005.00622.x","article-title":"Case series of 406 vernal keratoconjunctivitis patients: a demographic and epidemiological study.","volume":"84","author":"Leonardi","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"key":"R5-16-20210128","first-page":"1097","article-title":"Prevalence of vernal keratoconjunctivitis: a rare disease Br J O","volume":"92","author":"Bremond-Gignac","year":"2008","journal-title":"phthalmol"},{"key":"R6-16-20210128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/bjophthalmol-2011-301376","article-title":"Vernal keratoconjunctivitis: an update.","volume":"97","author":"De Smedt","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R7-16-20210128","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/jop.2008.0103","article-title":"A large prospective observational study of novel cyclosporine 0.1 aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis.","volume":"25","author":"Ebihara","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"key":"R8-16-20210128","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1398-9995.2007.01414.x","article-title":"The differences of tear function and ocular surface findings in patients with atopic keratoconjunctivitis and vernal keratoconjunctivitis.","volume":"62","author":"Hu","year":"2007","journal-title":"Allergy"},{"key":"R10-16-20210128","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00055735-200012000-00016","article-title":"Ocular complications of topical, peri-ocular, and systemic corticosteroids.","volume":"11","author":"Carnahan","year":"2000","journal-title":"Curr Opin Ophthalmol"},{"key":"R11-16-20210128","first-page":"187","article-title":"Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response.","volume":"4","author":"Armaly","year":"1965","journal-title":"Invest ophthalmol"},{"key":"R12-16-20210128","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/sj.eye.6701895","article-title":"Corticosteroid-induced glaucoma: a review of the literature.","volume":"20","author":"Kersey","year":"2006","journal-title":"Eye (Lond)"},{"key":"R13-16-20210128","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/ACI.0b013e32833dfa28","article-title":"Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis.","volume":"10","author":"Bielory","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R14-16-20210128","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0002-9394(14)71128-6","article-title":"A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.","volume":"123","author":"Dell","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"R15-16-20210128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.ICL.0000092071.82938.46","article-title":"Long-term safety of loteprednol etabonate 0.2 in the treatment of seasonal and perennial allergic conjunctivitis.","volume":"30","author":"Ilyas","year":"2004","journal-title":"Eye Contact Lens"},{"key":"R16-16-20210128","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jaci.2004.12.011","article-title":"Roger Altounyan and the discovery of cromolyn (sodium cromoglycate).","volume":"115","author":"Howell","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"R17-16-20210128","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/thorax.55.11.913","article-title":"Inhaled disodium cromoglycate (DSCG) as maintenance therapy in children with asthma: a systematic review.","volume":"55","author":"Tasche","year":"2000","journal-title":"Thorax"},{"key":"R19-16-20210128","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/106002809302700515","article-title":"Nedocromil sodium.","volume":"27","author":"Parish","year":"1993","journal-title":"Ann Pharmacother"},{"key":"R20-16-20210128","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1183\/09031936.98.12010050","article-title":"Effects of cromolyn and nedocromil on ion currents in canine tracheal smooth muscle.","volume":"12","author":"Janssen","year":"1998","journal-title":"Eur Respir J"},{"key":"R23-16-20210128","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000231388","article-title":"Topical treatment of hay fever with disodium cromoglycate (DSCG) solution.","volume":"49","author":"Glazer","year":"1975","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"R24-16-20210128","first-page":"207","article-title":"Treatment of seasonal conjunctivitis: comparison of 2 and 4 sodium cromoglycate ophthalmic solutions.","volume":"19","author":"Vakil","year":"1984","journal-title":"Can J Ophthalmol"},{"key":"R25-16-20210128","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1365-2222.1992.tb02066.x","article-title":"Double-blind group comparative study of 2 nedocromil sodium eye drops with 2 sodium cromoglycate and placebo eye drops in the treatment of seasonal allergic conjunctivitis.","volume":"22","author":"Leino","year":"1992","journal-title":"Clin Exp Allergy"},{"key":"R26-16-20210128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1398-9995.1994.tb00817.x","article-title":"A double-blind group comparative study of ophthalmic sodium cromoglycate, 2 four times daily and 4 twice daily, in the treatment of seasonal allergic conjunctivitis.","volume":"49","author":"Leino","year":"1994","journal-title":"Allergy"},{"key":"R27-16-20210128","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bjo.78.5.365","article-title":"A double blind placebo controlled group comparative study of ophthalmic sodium cromoglycate and nedocromil sodium in the treatment of vernal keratoconjunctivitis.","volume":"78","author":"el Hennawi","year":"1994","journal-title":"Br J Ophthalmol"},{"key":"R28-16-20210128","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1365-2222.1999.00501.x","article-title":"Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis.","volume":"29","author":"Verin","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"R30-16-20210128","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1185\/030079908X261078","article-title":"Evaluation of the effects of olopatadine ophthalmic solution, 0.2 on the ocular surface of patients with allergic conjunctivitis and dry eye.","volume":"24","author":"Mah","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"R31-16-20210128","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1081-1206(10)61413-5","article-title":"An evaluation of the ocular drying effects of 2 systemic antihistamines: loratadine and cetirizine hydrochloride.","volume":"93","author":"Ousler","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R32-16-20210128","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.clinthera.2007.03.017","article-title":"3rd, Workman DA, Torkildsen GL. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis.","volume":"29","author":"Ousler","year":"2007","journal-title":"Clin Ther"},{"issue":"Suppl","key":"R33-16-20210128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2222.1982.tb03295.x","article-title":"Ketotifen in childhood allergic disease.","volume":"12","author":"Warner","year":"1982","journal-title":"Clin Allergy"},{"key":"R34-16-20210128","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2165\/00003495-199040030-00006","article-title":"Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders.","volume":"40","author":"Grant","year":"1990","journal-title":"Drugs"},{"key":"R36-16-20210128","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/jop.1994.10.665","article-title":"Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use.","volume":"10","author":"Yanni","year":"1994","journal-title":"J Ocul Pharmacol"},{"key":"R37-16-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/108076803762718132","article-title":"In vitro inhibition of human conjunctival mast-cell degranulation by ketotifen.","volume":"19","author":"Schoch","year":"2003","journal-title":"J Ocul Pharmacol Ther"},{"key":"R38-16-20210128","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/j.1365-2222.2007.02782.x","article-title":"Ocular antiallergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.","volume":"37","author":"Galatowicz","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"R39-16-20210128","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0149-2918(03)80199-6","article-title":"Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.","volume":"25","author":"Crampton","year":"2003","journal-title":"Clin Ther"},{"key":"R40-16-20210128","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1001\/archopht.121.5.626","article-title":"Efficacy of ketotifen fumarate 0.025 ophthalmic solution compared with placebo in the conjunctival allergen challenge model.","volume":"121","author":"Abelson","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R41-16-20210128","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00044011-200323050-00003","article-title":"Onset and duration of action of ketotifen 0.025 and emedastine 0.05 in seasonal allergic conjunctivitis: efficacy after repeated pollen challenges in the vienna challenge chamber.","volume":"23","author":"Horak","year":"2003","journal-title":"Clin Drug Investig"},{"key":"R42-16-20210128","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/01.iio.0000212136.77675.b1","article-title":"Elestat (epinastine HCl ophthalmic solution 0.05) as a therapeutic for allergic conjunctivitis.","volume":"46","author":"Trattler","year":"2006","journal-title":"Int Ophthalmol Clin"},{"key":"R43-16-20210128","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1254\/jjp.68.449","article-title":"Inhibitory effect of epinastine on superoxide generation by rat neutrophils.","volume":"68","author":"Fukuishi","year":"1995","journal-title":"Jpn J Pharmacol"},{"key":"R44-16-20210128","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1006\/bbrc.1996.5904","article-title":"A novel antiallergic drug epinastine inhibits IL-8 release from human eosinophils.","volume":"230","author":"Kohyama","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"R45-16-20210128","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000092001","article-title":"Epinastine hydrochloride antagonism against interleukin-4-mediated T cell cytokine imbalance in vitro.","volume":"140","author":"Kanai","year":"2006","journal-title":"Int Arch Allergy Immunol"},{"key":"R46-16-20210128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0149-2918(04)90004-5","article-title":"Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.","volume":"26","author":"Abelson","year":"2004","journal-title":"Clin Ther"},{"key":"R47-16-20210128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0149-2918(04)90003-3","article-title":"Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.","volume":"26","author":"Whitcup","year":"2004","journal-title":"Clin Ther"},{"key":"R48-16-20210128","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0149-2918(08)80050-1","article-title":"3rd, Gomes P. Ocular comfort and drying effects of three topical antihistaminemast cell stabilizers in adults with allergic conjunctivitis: a randomized, double-masked crossover study.","volume":"30","author":"Torkildsen","year":"2008","journal-title":"Clin Ther"},{"key":"R49-16-20210128","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/archopht.117.5.643","article-title":"Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs.","volume":"117","author":"Yanni","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"R50-16-20210128","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S1081-1206(10)62513-6","article-title":"Olopatadine inhibits TNFalpha release from human conjunctival mast cells.","volume":"84","author":"Cook","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R51-16-20210128","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1081-1206(10)62926-2","article-title":"Olopatadine inhibits antiimmunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells.","volume":"87","author":"Cook","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R52-16-20210128","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/ACI.0b013e328357d3ba","article-title":"Ophthalmic antihistamines and H1-H4 receptors.","volume":"12","author":"Wade","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R53-16-20210128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1081-1206(10)62814-1","article-title":"Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model.","volume":"81","author":"Abelson","year":"1998","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R54-16-20210128","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0002-9394(98)00044-0","article-title":"Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.","volume":"125","author":"Abelson","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"R55-16-20210128","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/S0149-2918(00)83044-1","article-title":"Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1 ophthalmic solution and nedocromil sodium 2 ophthalmic solution in the human conjunctival allergen challenge model.","volume":"22","author":"Butrus","year":"2000","journal-title":"Clin Ther"},{"key":"R56-16-20210128","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1185\/030079904125004330","article-title":"Clinical efficacy of olopatadine vs. epinastine ophthalmic solution in the conjunctival allergen challenge model.","volume":"20","author":"Lanier","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"R57-16-20210128","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1034\/j.1600-0420.2000.078s230052.x","article-title":"Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1 olopatadine hydrochloride versus 0.05 ketotifen fumarate.","volume":"230","author":"Aguilar","year":"2000","journal-title":"Acta Ophthalmol Scand Suppl"},{"key":"R58-16-20210128","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0149-2918(00)80055-7","article-title":"A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1 ophthalmic solution and ketotifen fumarate 0.025 ophthalmic solution in the conjunctival antigen challenge model.","volume":"22","author":"Berdy","year":"2000","journal-title":"Clin Ther"},{"key":"R59-16-20210128","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1034\/j.1600-0420.2000.078s230064.x","article-title":"A forced choice comfort study of olopatadine hydrochloride 0.1 versus ketotifen fumarate 0.05.","volume":"230","author":"Artal","year":"2000","journal-title":"Acta Ophthalmol Scand Suppl"},{"key":"R60-16-20210128","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF02850255","article-title":"Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: a real-world comparison of efficacy and ocular comfort.","volume":"20","author":"Ganz","year":"2003","journal-title":"Adv Ther"},{"key":"R61-16-20210128","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1517\/17425255.4.4.453","article-title":"Olopatadine 0.2 ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing.","volume":"4","author":"Abelson","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R62-16-20210128","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1089\/jop.2005.21.400","article-title":"Efficiency of olopatadine hydrochloride 0.1 in the treatment of vernal keratoconjunctivitis and goblet cell density.","volume":"21","author":"Corum","year":"2005","journal-title":"J Ocul Pharmacol Ther"},{"key":"R63-16-20210128","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1755-3768.1994.tb07192.x","article-title":"Local specific immunotherapy in allergic conjunctivitis.","volume":"72","author":"Del Prete","year":"1994","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"R65-16-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000346335","article-title":"Sublingual immunotherapy for experimental allergic conjunctivitis in a murine model induced by Dermatophagoides farinae allergen.","volume":"161","author":"Liu","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"R66-16-20210128","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1185\/030079907X226096","article-title":"Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study.","volume":"23","author":"Cadario","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"R67-16-20210128","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jaci.2007.04.008","article-title":"Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study.","volume":"120","author":"Pajno","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"R68-16-20210128","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2332\/allergolint.11-OA-0388","article-title":"Evaluation of eosinophilic inflammation in a novel murine atopic keratoconjunctivitis model induced by crude Dermatophagoides farinae antigen.","volume":"61","author":"Hara","year":"2012","journal-title":"Allergol Int"},{"key":"R69-16-20210128","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ajo.2008.05.012","article-title":"Acquisition of vernal and atopic keratoconjunctivitis after bone marrow transplantation.","volume":"146","author":"Tabbara","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R70-16-20210128","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/bjo.2007.122044","article-title":"Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis.","volume":"91","author":"Mantelli","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R71-16-20210128","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0002-9394(14)77061-8","article-title":"Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis.","volume":"110","author":"Secchi","year":"1990","journal-title":"Am J Ophthalmol"},{"key":"R72-16-20210128","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1081-1206(10)61958-8","article-title":"Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis.","volume":"89","author":"Pucci","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R73-16-20210128","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1399-3038.2006.00427.x","article-title":"Efficacy of 1.25 and 1 topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood.","volume":"17","author":"Spadavecchia","year":"2006","journal-title":"Pediatr Allergy Immunol"},{"key":"R74-16-20210128","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3129\/i06-061","article-title":"Topical 2 cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis.","volume":"41","author":"Kilic","year":"2006","journal-title":"Can J Ophthalmol"},{"key":"R75-16-20210128","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/jop.2009.0087","article-title":"A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1 in severe allergic conjunctivitis.","volume":"26","author":"Ohashi","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"R76-16-20210128","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/bjophthalmol-2011-300415","article-title":"Topical ciclosporin in the treatment of vernal keratoconjunctivitis in Rwanda, Central Africa: a prospective, randomised, double-masked, controlled clinical trial.","volume":"96","author":"De Smedt","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R77-16-20210128","first-page":"177","article-title":"A double-masked comparison of 0.1 tacrolimus ointment and 2 cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children.","volume":"30","author":"Labcharoenwongs","year":"2012","journal-title":"Asian Pac J Allergy Immunol"},{"key":"R78-16-20210128","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-6420(00)00092-0","article-title":"Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term follow-up.","volume":"107","author":"Bonini","year":"2000","journal-title":"Ophthalmology"},{"key":"R79-16-20210128","first-page":"88","article-title":"Ocular complications of vernal keratoconjunctivitis.","volume":"34","author":"Tabbara","year":"1999","journal-title":"Can J Ophthalmol"},{"key":"R80-16-20210128","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/ACI.0b013e32833e16e4","article-title":"Atopic keratoconjunctivitis and atopic dermatitis.","volume":"10","author":"Guglielmetti","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R81-16-20210128","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-J","article-title":"The mechanism of action of cyclosporin A and FK506.","volume":"13","author":"Schreiber","year":"1992","journal-title":"Immunol Today"},{"key":"R82-16-20210128","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/archopht.119.10.1512","article-title":"Effects of cyclosporin A on human conjunctival fibroblasts.","volume":"119","author":"Leonardi","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"R83-16-20210128","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2332\/allergolint.55.121","article-title":"Fibroblasts as local immune modulators in ocular allergic disease.","volume":"55","author":"Fukuda","year":"2006","journal-title":"Allergol Int"},{"key":"R84-16-20210128","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/eye.2001.10","article-title":"Topical cyclosporin A in the management of vernal keratoconjunctivitis.","volume":"15","author":"Gupta","year":"2001","journal-title":"Eye (Lond)"},{"key":"R85-16-20210128","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/039463201002300322","article-title":"Long-term safety and efficacy of topical cyclosporine in 156 children with vernal keratoconjunctivitis.","volume":"23","author":"Pucci","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"key":"R86-16-20210128","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ophtha.2003.05.035","article-title":"A randomized trial of topical cyclosporin 0.05 in topical steroid-resistant atopic keratoconjunctivitis.","volume":"111","author":"Akpek","year":"2004","journal-title":"Ophthalmology"},{"key":"R87-16-20210128","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/bjo.2005.082461","article-title":"Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis.","volume":"90","author":"Daniell","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R88-16-20210128","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0161-6420(98)99043-1","article-title":"A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis.","volume":"105","author":"Hingorani","year":"1998","journal-title":"Ophthalmology"},{"key":"R89-16-20210128","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.4049\/jimmunol.146.7.2374","article-title":"FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI cells.","volume":"146","author":"de Paulis","year":"1991","journal-title":"J Immunol"},{"key":"R90-16-20210128","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaci.2003.10.065","article-title":"Vernal keratoconjunctivitis: result of a novel therapy with 0.1 topical ophthalmic FK-506 ointment.","volume":"113","author":"Vichyanond","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"R91-16-20210128","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1016\/j.jaci.2006.11.536","article-title":"Vernal keratoconjunctivitis (VKC) treated with 0.1 FK-506 ophthalmic ointment result of three years follow-up.","volume":"119","author":"Pacharn","year":"2007","journal-title":"J Allergy Clin Immunol"}],"container-title":["Current Opinion in Allergy & Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACI.0b013e328364d86a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T02:03:24Z","timestamp":1715911404000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130832-201310000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":84,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/aci.0b013e328364d86a","relation":{},"ISSN":["1528-4050"],"issn-type":[{"value":"1528-4050","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}